EXANTE Appoints Robert Parker as Head of Risk, Financial Markets
LONDON, UNITED KINGDOM, May 22, 2025 / EINPresswire.com / -- Leading global prime broker EXANTE is pleased to announce the appointment of Robert Parker as Head of Risk, Financial Markets, effective 12 May 2025. Based in London, Parker will report directly to Zane Kotane, Chief Operations Officer.
With over 25 years of experience in financial services, Parker brings a wealth of expertise across Market Risk, Credit Risk, Operational Risk, and Liquidity Risk. He has held senior risk management roles at BCS Global Markets, Sberbank CIB, Deutsche Bank, MF Global, and BGC Partners/Cantor Fitzgerald, following an early career in options market making on the LIFFE trading floor.
Throughout his career, Parker has successfully designed and implemented risk management frameworks that align closely with business strategy. His collaborative approach and deep understanding of complex risk environments make him well positioned to support EXANTE's evolving needs.
Zane Kotane, COO of EXANTE, commented: 'I'm delighted to welcome Robert to the EXANTE team. Robert's broad experience and leadership will be instrumental as we enhance our risk frameworks, support product innovation such as our options trading initiatives, and refine liquidity management processes. His appointment reflects our commitment to maintaining robust, forward-looking risk practices that support our long-term growth and deliver enhanced value to our clients.'
Robert Parker added: 'Joining EXANTE at such an exciting stage in its journey is a tremendous opportunity. I look forward to working with colleagues across the business to further strengthen the risk function, support innovation, and help drive sustainable growth in line with EXANTE's strategic objectives.'
About EXANTE
EXANTE is a leading global prime broker offering access to 50+ global financial markets, 8 asset classes and 1m+ instruments, from one easy multi-currency account, using proprietary technology. It offers fully customisable solutions, advanced trading modules, and robust infrastructure. With a commitment to excellence, transparency, and client satisfaction, EXANTE offers comprehensive brokerage services to individual and institutional investors worldwide.
Media Contact: Julia Chapman, [email protected]
Julia Chapman
EXANTE
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
AI could lead to more job cuts at BT, says chief executive
The chief executive of BT has said that advances in artificial intelligence could presage deeper jobs cuts at the FTSE 100 telecoms company, which has already outlined plans to shed up to 55,000 workers. Two years ago, the company said that between 40,000 and 55,000 jobs would be axed as it set out to become a 'leaner' business by the end of the decade. However, in a weekend interview, its chief executive, Allison Kirkby, said the plan, which includes stripping out £3bn of costs, 'did not reflect the full potential of AI'. 'Depending on what we learn from AI … there may be an opportunity for BT to be even smaller by the end of the decade,' Kirkby said in an interview with the Financial Times. BT, which is the biggest broadband provider in the country, laid out plans in 2023 to cut the size of its workforce, including contractors, by 2030. Philip Jansen, who was chief executive at the time, said the company could rely on a much smaller workforce and cost base by the end of the decade. Kirkby, who took over from Jansen last year, has pushed for the company to streamline its operations – selling its Italian business and its Irish wholesale and enterprise unit – and focus more on improving in the UK. Last month, BT spun off its international business into a separate division, but is reportedly open to offers for this area of the business, according to the FT, which cited a person familiar with the matter. Kirkby also said she did not think the value of BT's broadband network business Openreach was reflected in its share price. If this continued, BT 'would absolutely have to look at options'. The 'time to reconsider' whether to spin off the business would take place once it has completed upgrading its network to full fibre, she said. However, Kirkby said her preference would be for the BT share price to reflect the worthof Openreach rather than to spin it off. It emerged last week that BT was weighing up a potential takeover of the telecoms and broadband company TalkTalk. Its smaller rival has about 3.2 million customers, although it has struggled since it was taken private by Toscafund, a London-based investment firm, in a £1.1bn deal that added £527m of debt to its balance sheet in 2021.
Yahoo
36 minutes ago
- Yahoo
Fortnum & Mason plots first UK stores outside London
Fortnum & Mason is plotting its first UK stores outside of London after a surge in customer demand for regular top-ups of luxury teas, biscuits and jam. Tom Athron, the chief of the luxury retailer, said he would be interested in opening stores 'up the spine of the country', adding: 'We do like the idea of stepping beyond Piccadilly [where it has its flagship store], and certainly stepping beyond London.' Fortnum & Mason currently only has four UK stores – including at St Pancras station, a 'tea salon' in London and Heathrow Terminal 5, as well as one site in Hong Kong. Opening outside London would mark the first time the Royal grocer has set up a permanent UK base away from the capital in its 318-year-history. Mr Athron did not say where a new Fortnums could open – but said he would look at sites in a 'beautiful location' with 'beautiful architecture'. He suggested Fortnum would probably consider opening one or two outposts, adding: 'This isn't about ubiquity. But there are other locations across the country where we think that Fortnum could offer both retail and restaurants, where it would be relevant. And we're looking at those now.' It comes as the retailer said it was no longer seen as a 'Christmas focused' business, with customers using Fortnum & Mason to 'stock their own larders' throughout the year. Fortnum & Mason earlier this month launched a new membership scheme – with those signing up to the 'Friends of Fortnum's' programme getting access to tickets for dining events as well as free delivery. Mr Athron said any new store away from London would 'remove the barriers' for the membership scheme and allow members to attend these events. Fortnum & Mason will also look at opportunities to open more airport stores, with Mr Athron saying: 'We would love the opportunity to have shops and restaurants in every terminal at Heathrow.' The plans come despite signs that households are slamming the brakes on spending, amid concerns over the economy. Figures from the British Retail Consortium last week suggested retail sales rose by just 1pc in the year to May. Mr Athron said Fortnum was not seeing a drop in demand. He said: 'What we tend to find is that when people become more judicious in the way that they spend their money, they switch out handbags and trainers for small luxuries they can take home – things like a really special jar of jam.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
With up to three years of follow-up, a single dose of lonvo-z led to a 98% mean reduction in monthly HAE attack rate in all 10 patients All 10 patients were attack-free and treatment-free for a median of 23 months through the latest follow-up, demonstrating the potential of lonvo-z to become the first one-time therapy for most HAE patients Lonvo-z was well tolerated and continues to demonstrate a favorable safety profile The global Phase 3 HAELO trial of lonvo-z has concluded screening ahead of schedule with more than half screened from U.S. sites; Intellia to provide an update on enrollment in the future CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom. 'Today's results underscore the promising potential of Intellia's approach to gene editing therapy – a one-time treatment that was well tolerated and offered a highly differentiated, durable effect for patients suffering from a serious disease,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'Seeing all 10 patients in the Phase 1 portion of this study free from both HAE attacks and chronic therapy at nearly two years of median follow-up is incredibly encouraging. These data fuel our optimism for the outcomes of our ongoing Phase 3 HAELO study, which we expect to report in the first half of 2026, and highlight the strong value we believe it will offer patients, physicians and payers.' 'People living with HAE often report a reduced quality of life because they worry about the likelihood of their next attack, either because they still experience attacks or are reminded of it by their use of chronic therapy,' said Dr. Joshua Jacobs, Medical Director, Allergy and Asthma Clinical Research, Inc. 'Based on the data, it is reasonable to expect lonvo-z could offer patients the potential to be free from both physical HAE attacks and the burden of managing chronic HAE treatment.' In the Phase 1 portion of the study, a one-time dose of 25 mg (N=3), 50 mg (N=4) or 75 mg (N=3) of lonvo-z was administered via intravenous infusion and plasma kallikrein protein levels were measured along with HAE attacks. At the time of the February 12 data cutoff, patients were attack-free and treatment-free for a median of nearly two years. With up to three years of follow-up, a single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% over the study period, compared to pre-treatment baseline. For all 10 patients, deep, dose-dependent and durable reductions in plasma kallikrein protein continued to be observed through the latest assessment. Safety Across all three dose levels, lonvo-z has been well tolerated and continues to demonstrate a favorable safety profile consistent with earlier data presented at EAACI in 2024. The most frequent adverse events during the study period were infusion-related reactions (IRRs). IRRs were mostly Grade 1 and resolved with all patients receiving the full dose. With up to 3 years of follow-up, no treatment-emergent serious adverse events were observed, and no treatment-related adverse events were observed during the period following 28 days after dosing. Clinical Development PlansIntellia's global Phase 3, randomized, double-blind, placebo-controlled HAELO trial is ongoing to assess the safety and efficacy of lonvo-z at the 50 mg dosage. The Company announced today the HAELO trial has successfully completed screening ahead of schedule, with over half of the patients being screened in the United States. The study is no longer recruiting and Intellia will provide an update on enrollment in the future. New and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study is planned to be presented in the second half of 2025. Intellia expects to submit a biologics license application (BLA) in 2026 to support the Company's plans for a U.S. launch in 2027. For more information on HAELO (NCT06634420), please visit About the Lonvoguran Ziclumeran (lonvo-z, also known as NTLA-2002) Clinical ProgramIntellia's ongoing Phase 1/2 study is evaluating the safety and efficacy of lonvo-z in adults with Type I or Type II hereditary angioedema (HAE). The Phase 1 portion of the study is an international, open-label study designed to identify the dose level of lonvo-z selected for further evaluation in the Phase 2 portion of the study. Enrollment in both portions of the Phase 1/2 study is complete. Intellia dosed the first patient in the global Phase 3, randomized, double-blind, placebo-controlled HAELO trial in January of 2025. Visit (NCT05120830) for more details. About Lonvo-zBased on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy designed to prevent HAE attacks by inactivating the kallikrein B1 (KLKB1) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. About Intellia TherapeuticsIntellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at and follow us @intelliatx. Forward-Looking Statements This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations concerning: the safety, efficacy, success and advancement of its clinical programs for lonvoguran ziclumeran or 'lonvo-z' (also known as NTLA-2002) for hereditary angioedema ('HAE'), including the ability to successfully complete its global Phase 3 HAELO study; its expectation to present additional data regarding lonvo-z, including reporting outcomes of the Phase 3 HAELO study in the first half of 2026 and presenting new and longer-term data from the Phase 2 portion of the ongoing Phase 1/2 study of lonvo-z in the second half of 2025; and its expectation to be able to support a biologics license application for lonvo-z for the treatment of HAE by 2026 for a U.S. launch in 2027. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to Intellia's relationship with third parties, including its contract manufacturers, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including lonvo-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to complete the Phase 3 HAELO study for HAE; the risk that any one or more of Intellia's product candidates, including lonvo-z, will not be successfully developed and commercialized; and the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report of Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by ChavesSenior Manager, Investor Media:Matt CrensonTen Bridge Communicationsmcrenson@
